23,433 Shares of Avalyn Pharma Inc. $AVLN Purchased by Profund Advisors LLC

Profund Advisors LLC bought a new stake in shares of Avalyn Pharma Inc. (NASDAQ:AVLN) in the 3rd quarter, HoldingsChannel.com reports. The fund bought 23,433 shares of the company’s stock, valued at approximately $668,000.

A number of other hedge funds have also made changes to their positions in AVLN. China Universal Asset Management Co. Ltd. purchased a new position in Avalyn Pharma during the third quarter worth about $29,000. Manchester Capital Management LLC acquired a new stake in Avalyn Pharma during the 3rd quarter worth approximately $36,000. Bank of New York Mellon Corp purchased a new position in Avalyn Pharma in the second quarter worth $1,321,000. State Street Corp acquired a new position in shares of Avalyn Pharma during the 2nd quarter worth $10,501,000. Finally, Braidwell LP acquired a new stake in shares of Avalyn Pharma during the 2nd quarter worth about $26,382,000.

Avalyn Pharma Price Performance

Shares of AVLN opened at $27.47 on Thursday. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. Avalyn Pharma Inc. has a one year low of $22.24 and a one year high of $40.17. The company has a 50-day moving average price of $29.47.

Avalyn Pharma (NASDAQ:AVLN) last released its earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.05. As a group, analysts expect that Avalyn Pharma Inc. will post -3.86 EPS for the current year.

Analyst Ratings Changes

AVLN has been the topic of a number of recent research reports. Wall Street Zen cut Avalyn Pharma from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Morgan Stanley raised their target price on Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Raymond James Financial started coverage on Avalyn Pharma in a research report on Friday, October 2nd. They issued an “outperform” rating and a $60.00 price target for the company. Finally, Weiss Ratings started coverage on Avalyn Pharma in a research report on Thursday, August 13th. They issued a “sell (d+)” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Avalyn Pharma has an average rating of “Moderate Buy” and a consensus target price of $60.00.

About Avalyn Pharma

Avalyn Pharma, Inc (NASDAQ: AVLN) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with pulmonary fibrosis and other serious respiratory diseases. The company’s research is aimed at delivering established antifibrotic medicines directly to the lungs, with the potential to improve treatment effectiveness while reducing systemic exposure and associated side effects.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.